
Pro-Dex (PDEX) Stock Forecast & Price Target
Pro-Dex (PDEX) Analyst Ratings
Bulls say
Pro-Dex Inc has demonstrated a significant year-over-year revenue increase of 22%, primarily driven by heightened sales in new medical device products and repairs. The company has also improved its gross margins to 33%, indicating enhanced operational efficiency and profitability. Furthermore, the proactive management strategy of securing new product contracts and investing in private label products has established a robust growth trajectory for the organization.
Bears say
Pro-Dex Inc has revised its FY25 revenue estimates down to $67 million from $68 million, alongside a decrease in EPS expectations from $2.30 to $2.81. The company faces significant risks related to fluctuating demand for technology, competition within the medical device sector, and broader economic conditions that may affect consumer sentiment and industry growth. These factors contribute to a negative outlook on the stock, indicative of potential challenges in achieving financial targets in the foreseeable future.
This aggregate rating is based on analysts' research of Pro-Dex and is not a guaranteed prediction by Public.com or investment advice.
Pro-Dex (PDEX) Analyst Forecast & Price Prediction
Start investing in Pro-Dex (PDEX)
Order type
Buy in
Order amount
Est. shares
0 shares